Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-4 of 4
Keywords: Pathological complete response
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Hormone Receptor and HER2 Status Switch in Non-pCR Breast Cancer Specimens after Neoadjuvant Therapy
Available to PurchaseMoritz Dimpfl, Doris Mayr, Elisa Schmoeckel, Tom Degenhardt, Tanja K. Eggersmann, Nadia Harbeck, Rachel Wuerstlein
Journal:
Breast Care
Breast Care (2022) 17 (5): 501–507.
Published Online: 27 April 2022
...: Tumor samples from patients without pathological complete response (non-pCR) were evaluated. Pathological complete response (pCR) was defined as no invasive tumor in breast and lymph nodes (ypT0/is ypN0). HR and HER2 status determined before NAC was compared with the corresponding receptor status...
Journal Articles
Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Available to PurchaseMarius Wunderle, Lothar Häberle, Alexander Hein, Sebastian M. Jud, Michael P. Lux, Carolin C. Hack, Julius Emons, Felix Heindl, Naiba Nabieva, Christian R. Loehberg, Rüdiger Schulz-Wendtland, Arndt Hartmann, Matthias W. Beckmann, Peter A. Fasching, Paul Gass
Journal:
Breast Care
Breast Care (2021) 16 (3): 254–262.
Published Online: 01 July 2020
..., a pathological complete response (pCR) has been described as generally resulting in a favorable prognosis. However, there are subgroups, such as patients with a mutation in BRCA1 or BRCA2 ,in which the effect of pCR on the prognosis is suspected to be weaker. Patients with a family history of breast...
Journal Articles
Standard Neoadjuvant Treatment in Early/Locally Advanced Breast Cancer
Available to Purchase
Journal:
Breast Care
Breast Care (2018) 13 (4): 244–249.
Published Online: 03 August 2018
... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Breast cancer Neoadjuvant treatment Pathological complete response...
Journal Articles
Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer
Available to Purchase
Journal:
Breast Care
Breast Care (2016) 11 (2): 96–100.
Published Online: 26 April 2016
... and, therefore, enables a breast-conserving surgery. Furthermore, it allows monitoring of therapy response. In particular, in HER2-positive and triple-negative breast cancer (TNBC) the achievement of a pathological complete response (pCR) is associated with a favorable long-term survival [ 20 ]. However...